The Curative Effect of Using Simvastatin, Pioglitazone Hydrochloride and Levamlodipine Besylate Jointly to Treat the Metabolic Syndrome_West China Medical Journal

Authors：

YIN Libo ¹ , WANG Chunmei ¹ , GUO Minxia ¹ , et al ²

Department of Cardiology, the Red Cross Hospital of Leshan, Leshan 614000, China;

Corresponding author：

Keywords：

代谢综合征; 吡格列酮; 辛伐他汀; 苯磺酸左旋氨氯地平; 治疗

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的:观察辛伐他汀、吡格列酮和苯磺酸左旋氨氯地平联合治疗代谢综合征疗效。方法:76例初诊代谢综合征患者,服用吡格列酮15mg/d、苯磺酸左旋氨氯地平25mg/d、辛伐他汀10mg/d,疗程1个月。观察治疗前后血压、腰围、体重指数、血糖、血胰岛素、血尿酸和血脂水平等变化。结果:患者治疗后血糖、血脂、胰岛素水平、血压均明显降低,差别有统计学意义(P lt;001)。腰围、体重指数略有下降,无统计学意义,血尿酸变化不明显。结论:吡格列酮、辛伐他汀和苯磺酸左旋氨氯地平联合治疗代谢综合征能够改善胰岛素抵抗和代谢异常,疗效可靠、服药简单、依从性好,效价比合理,无不良反应。

Citation： YIN Libo,WANG Chunmei,GUO Minxia,et al. The Curative Effect of Using Simvastatin, Pioglitazone Hydrochloride and Levamlodipine Besylate Jointly to Treat the Metabolic Syndrome. West China Medical Journal, 2009, 24(5): 1122-1124. doi: Copy

1.	ALBERTI K G, ZIMMET P Z. Definition, diagnosis and classification of diabetes mellitus and its complications, part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J]. Diabet Med, 1998, 15(7): 539553.
2.	BALKAU B, CHARLES M A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)[J]. Diabet Med, 1999,16(5): 442443.
3.	National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report[J]. Circulation, 2002, 106 (25):31433421.
4.	金文胜,潘长玉.国际糖尿病联盟关于代谢综合证定义的全球共识[J].中华内分泌代谢杂志, 2005, 21(4):412.
5.	田慧,潘长玉,陆菊明,等.老年男性人群2型糖尿病与代谢综合征情况调查[J].中华老年多器官疾病杂志,2002,1(1):19.
6.	徐成斌.代谢综合征[J]. 国外医学内分泌学分册,2005,25(1):36.
7.	M ARIOLIS A, A LEVIZOS A, KOMPOTI M. Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes[J]. Cardiovasc Diabetol,2006, 5(1): 21.
8.	HAN T S, WILLIAMS K, SATTAR N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study[J]. Obes Res,2002,10:923931[9]STEINBERGER J. Diagnosis of the metabolic syndrome in children[J]. Curr Opin Lipidol,2003,14:555559.
9.	MAISON P, BYRNE C D, HALES C N, et al. Do different dimensions of the metabolic syndrome change together overtime? Evidence supporting obesity as the central feature[J]. Diabetes Care,2001,24:17581763.
10.	HAFFNER S, TAEGT MEYER H. Epidemic obesity and the metabolic syndrome[J]. Circulation, 2003, 108(13):15411545.
11.	LEBOVITZ H E. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus[J]. Am J Cardiol, 2002,90(5A):34 41.
12.	PATRICIA I, TAKALA T, OIKONEN V, et al. Effect of during physiological hyperinsu linemia [J]. Diabetes Care, 2004, 27: 21722177.
13.	KAIN K, CATTO A J, GRANT P J. Associations between insulin resistance and thrombotic risk factors in high risk South Asian subjects[J]. Diabet Med, 2003, 20:651655.
14.	DAVIGNON J, MONTIGNY M, DUFOUR R. HMGCoA reductase inhibitors: a look back and a look ahead[J]. Can J Cardiol, 1992,8(8):843864.
15.	ROSMOND R, CHAGNON Y C, HOLM G, et al. Hypertension in obesity and leptin receptor gene locus[J]. J Clin Endocrinol Metab,2000,85:31263131.
16.	ARROWSMITH J E, CAMPBELL S F, CROSS P E, ABOTT RD, CELIS H, STAESSEN JA, et al. Longacting dihydropyruding calcium antagonista.1,2alkoxymethel derivatives incorporating basic substicents[J]. J Med Chem,1986,29(14):1 697701.
17.	胡大一,赵秀丽,孙宁玲,等.苯磺酸左旋胺氯地平与苯磺酸氨氯地平治疗原发性轻中度高血压的随机、双盲平行研究[J]. 中国医刊, 2002,5(1):4751.

1. ALBERTI K G, ZIMMET P Z. Definition, diagnosis and classification of diabetes mellitus and its complications, part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J]. Diabet Med, 1998, 15(7): 539553.
2. BALKAU B, CHARLES M A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)[J]. Diabet Med, 1999,16(5): 442443.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report[J]. Circulation, 2002, 106 (25):31433421.
4. 金文胜,潘长玉.国际糖尿病联盟关于代谢综合证定义的全球共识[J].中华内分泌代谢杂志, 2005, 21(4):412.
5. 田慧,潘长玉,陆菊明,等.老年男性人群2型糖尿病与代谢综合征情况调查[J].中华老年多器官疾病杂志,2002,1(1):19.
6. 徐成斌.代谢综合征[J]. 国外医学内分泌学分册,2005,25(1):36.
7. M ARIOLIS A, A LEVIZOS A, KOMPOTI M. Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes[J]. Cardiovasc Diabetol,2006, 5(1): 21.
8. HAN T S, WILLIAMS K, SATTAR N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study[J]. Obes Res,2002,10:923931[9]STEINBERGER J. Diagnosis of the metabolic syndrome in children[J]. Curr Opin Lipidol,2003,14:555559.
9. MAISON P, BYRNE C D, HALES C N, et al. Do different dimensions of the metabolic syndrome change together overtime? Evidence supporting obesity as the central feature[J]. Diabetes Care,2001,24:17581763.
10. HAFFNER S, TAEGT MEYER H. Epidemic obesity and the metabolic syndrome[J]. Circulation, 2003, 108(13):15411545.
11. LEBOVITZ H E. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus[J]. Am J Cardiol, 2002,90(5A):34 41.
12. PATRICIA I, TAKALA T, OIKONEN V, et al. Effect of during physiological hyperinsu linemia [J]. Diabetes Care, 2004, 27: 21722177.
13. KAIN K, CATTO A J, GRANT P J. Associations between insulin resistance and thrombotic risk factors in high risk South Asian subjects[J]. Diabet Med, 2003, 20:651655.
14. DAVIGNON J, MONTIGNY M, DUFOUR R. HMGCoA reductase inhibitors: a look back and a look ahead[J]. Can J Cardiol, 1992,8(8):843864.
15. ROSMOND R, CHAGNON Y C, HOLM G, et al. Hypertension in obesity and leptin receptor gene locus[J]. J Clin Endocrinol Metab,2000,85:31263131.
16. ARROWSMITH J E, CAMPBELL S F, CROSS P E, ABOTT RD, CELIS H, STAESSEN JA, et al. Longacting dihydropyruding calcium antagonista.1,2alkoxymethel derivatives incorporating basic substicents[J]. J Med Chem,1986,29(14):1 697701.
17. 胡大一,赵秀丽,孙宁玲,等.苯磺酸左旋胺氯地平与苯磺酸氨氯地平治疗原发性轻中度高血压的随机、双盲平行研究[J]. 中国医刊, 2002,5(1):4751.

West China Medical Journal

The Curative Effect of Using Simvastatin, Pioglitazone Hydrochloride and Levamlodipine Besylate Jointly to Treat the Metabolic Syndrome

Abstract Full text Figures/Tables Video References Cited by

Format

Content